Friday, 17 Aug 2018

You are here

The RheumNow Week in Review – Good News for GPA, CZP, Tofa but not ERA (6.1.18)

Dr. Jack Cush reviews this weeks reports from RheumNow.com, including the risk of autoimmunity with vaccination, early RA outcomes, new FDA approvals for certolizumab and tofacitinib and the risk of death from infection with biologics.

  1. UCB announces the FDA has approved Cimzia (certolizumab) for use in moderate to severe plaque psoriasis based on over 1000 pts in Phase 3 RCTs CIMPASI-1, CIMPASI-2 and CIMPACT and PASI75 of 75-82% at wk16. Certolizumab is now FDA approved for use in Crohns disease, Rheumatoid arthritis, Ankylosing spondylitis, psoriatic arthritis and now Psoriasis. https://t.co/PYx15htd3Z
  2. Pfizer announces that the FDA has approved Xeljanz (tofacitinib) 10 mg twice-daily (BID) for at least 8 Wks, followed by 5 mg BID or 10 mg BID, for adults with active ulcerative colitis (UC). This is 1st approval of 10mg bid dose https://t.co/z5hb5p8psF
  3. In RCTs, among 1157 ulcerative colitis pts receiving tofacitinib, 65 (5.6%) developed herpes zoster, 11 multidermatomal & 1 HZ encephalitis. HZ=4.07 with higher risk in elderly, Asians, prior TNFi failure & tofa 10 mg bid. http://bit.ly/2kEOjzH
  4. CMAJ reports on a Canadian population study of 290,939 girls 12–17 yrs who received quadravalent HPV vaccine with no increased risk of subsequent autoimmune disease (eg, Graves, Bells, JIA, SLE, AIHA, etc) https://t.co/jtJBDlE6jv
  5. US Renal Transplant system review ~20 yr data shows Renal transplantation results in a significant decrease (70%) in mortality among ESRD GPA patients, largely due to a 90% decrease in CVD death. https://t.co/vdWwGxJMvO 
  6. ESPOIR 5 Yr study of 403 early RA patients shows radiographic progression occurred in 143 (35.5%), more likely with high dose steroids and less likely with >36 mos of biologic therapy. https://t.co/onKuurpwZL 
  7. In a DMARD naive, early RA cohort (U-Act) study, 52% were MTX-IR at 1 year;  predictors of inadequate response to MTX included higher DAS28 (OR=2), current smoking (OR=3) and no alcohol consumption. https://t.co/FTxv5ZxObP
  8. British Biologics Registry of 19282 RA patients -the biologic SIE rate was 5.51 per 100 patient-yrs. The risk of death in the first 30days following a serious infection was 10% https://t.co/sIwd9S8QJM
  9. Increased Risk of Depression and Anxiety in Rheumatoid Arthritis  
  10. Cancer Risk Raised in Psoriatic Arthritis  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review – We’re Number One! (8.17.18)

Dr. Cush reviews the articles and news from the last week on RheumNow.com. Info on comorbidities, the down side of steroids, unmet need in psoriatic arthritis and the top 10 Rheumatology programs.

U.S. News 2018-19 Rheumatology Rankings

The Annual U.S. News and World Report Rankings of Hospitals has listed the top contenders in the field of rheumatology. The U.S. News Review rates hospitals nationwide in 16 specialties – including rheumatology. Of the 4,500 hospitals covered by U.S. News that were analyzed, 158 were classified nationally in at least one specialty area.

The RheumNow Week in Review – No Good Gout (8.10.18)

Dr. Jack Cush reviews the news and latest journal articles from the past week on RheumNow.com. Info on Surgery and Hip Fractures, Gout drugs abandoned, Allopurinol escalation, hydroxychloroquine drug levels, how to treat scleroderma in India and exactly who gets back pain.

The RheumNow Week in Review – Handshakes or Hugs (8.3.18)

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com, including new treatments for LTBI, gout consequences, RA and offspring risk, PsA risk, and the opioid epidemic effects.

The RheumNow Week in Review – Lupus in the News (7.27.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.